{"id":"8ccb8a606c6c","type":"article","url":"https://hartvaat.nl/2017/05/01/aanhoudende-bloeddrukreductie-met-baroreceptoractivatietherapie-6-jaarsfollow-up/","title":"Aanhoudende bloeddrukreductie met baroreceptoractivatietherapie: 6-jaarsfollow-up","title_en":"Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["bloeddrukbehandeling"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.117.09086","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.117.09086","authors":["Peter W de Leeuw","John D Bisognano","George L Bakris","Mitra K Nadim","Hermann Haller","Abraham A Kroon"],"significance":7,"published":"2017-05-01","source_date":"2017-05-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/resistente-hypertensie/","https://hartvaat.nl/kennis/hypertensie/alfa-blokkers-hypertensie/"],"congress":"","summary_en":"Six-year follow-up of baroreflex activation therapy for resistant hypertension showed sustained blood pressure reduction, providing the longest-term data supporting this device-based approach for treatment-resistant blood pressure.","created":"2026-07-03T10:26:41Z","updated":"2026-07-03T18:38:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"6-jaars open follow-upresultaten van baroreceptoractivatietherapie (BAT) voor therapieresistente hypertensie. Langetermijndata die duurzame bloeddrukreductie bevestigen.","abstract_original":"Baroreflex activation therapy is a novel technique for treating patients with resistant hypertension. Although short-term studies have demonstrated that it lowers blood pressure, long-term results have not yet been reported. The aim of the present study is to assess the long-term efficacy and safety of baroreflex activation therapy. Long-term follow-up data were analyzed from all patients who had been included in 1 of the 3 trials that focused on treatment-resistant hypertensive patients. Altogether, 383 patients were available for analysis: 143 of these had completed 5 years of follow-up and 48 patients had completed 6 years of follow-up. In the entire cohort, office systolic blood pressure fell from 179±24 mm Hg to 144±28 mm Hg (P<0.0001), whereas office diastolic pressure dropped from 103±16 mm Hg to 85±18 mm Hg (P<0.0001). Heart rate fell from 74±15 beats per minute to 71±13 beats per minute (P<0.02). The effect of baroreflex activation therapy is greater than average in patients with signs of heart failure and less than average in patients with isolated systolic hypertension. In ≈25% of patients, it was possible to reduce the number of medications from a median of 6 to a median of 3. Temporary side effects, related to either the surgical procedure or the cardiovascular instability, do occur, but they do not require specific measures and resolve over time.After a follow-up of 6 years, baroreflex activation therapy maintains its efficacy for persistent reduction of office blood pressure in patients with resistant hypertension without major safety issues."}